{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:25:50Z","timestamp":1789104350783,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejphar.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T02:32:15Z","timestamp":1533609135000},"page":"147-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["On the front lines of the opioid epidemic: Rescue by naloxone"],"prefix":"10.1016","volume":"835","author":[{"given":"Phil","family":"Skolnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.08.004_bib1","unstructured":"Adams, J., 2018. Surgeon General\u2019s advisory on naloxone and opioid overdose.\u00a0\u3008https:\/\/www.surgeongeneral.gov\/priorities\/opioid-overdose-prevention\/naloxone-advisory.html?Utm_campaign=Rx%20Summit&utm_source=hs_email&utm_medium=email&utm_content=62033785&_hsenc=p2ANqtz-8gpzM8wnU94-xrgcG7DYAAHY1MnbgWJF3myPsEulzbdDQs69aij2OvVDKkL7AKwib7B_jhdNfTpXzTB4mrs0P2RvYXg&_hsmi=62033785\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib3","unstructured":"Anson, P., 2016. AMA Drops pain as vital sign. \u3008https:\/\/www.painnewsnetwork.org\/stories\/2016\/6\/16\/ama-drops-pain-as-vital-sign\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib4","article-title":"Use of naloxone spray 4 mg in the community setting: a survey of use by community organizations","author":"Avetian","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2018.08.004_bib5","unstructured":"Blau, M., 2018. The next naloxone? Companies, academics search for better overdose-reversal drugs. \u3008https:\/\/www.statnews.com\/2018\/04\/10\/next-naloxone-overdose-reversal-drugs\/\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/M17-2224","article-title":"Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review","volume":"167","author":"Chou","year":"2017","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ejphar.2018.08.004_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.05.009","article-title":"Major increases in opioid analgesic abuse in the United States: concerns and strategies","volume":"81","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2018.08.004_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/clpt.1986.9","article-title":"Nalmefene: intravenous safety and kinetics of a new opioid antagonist","volume":"39","author":"Dixon","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-297","article-title":"Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study","author":"Doe-Simkins","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejphar.2018.08.004_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jama.2017.9308","article-title":"Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000\u20132015","volume":"318","author":"Dowell","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2018.08.004_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40122-015-0035-9","article-title":"Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery","volume":"4","author":"Edwards","year":"2015","journal-title":"Pain. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","article-title":"Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes","volume":"271","author":"Emmerson","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib17","doi-asserted-by":"crossref","unstructured":"Evans, W., Lieber, E., Power, P., 2018. How the reformulation of Oxycontin ignited the heroin epidemic. NBER Working Paper No. 24475, \u3008http:\/\/www.nber.org\/papers\/w24475\u3009. (Last Accessed May 2018).","DOI":"10.3386\/w24475"},{"key":"10.1016\/j.ejphar.2018.08.004_bib18","unstructured":"Federal Register, 2017. Determination that REVEX (nalmefene hydrochloride injection, 0.1 mg base\/millilitre and 1.0 mg base\/millilitre, was not withdrawn from sale for reasons of safety or effectiveness. \u3008https:\/\/www.federalregister.gov\/documents\/2017\/11\/03\/2017-23952\/determination-that-revex-nalmefene-hydrochloride-injection-01-milligram-basemilliliter-and-10\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib19","unstructured":"Food and Drug Administration, 1995. Revex (nalmefene hydrochloride injection). \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020459s006lbl.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib20","unstructured":"Food and Drug Administration, 2014. Full prescribing information for Evzio. Reference ID: 3482803. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020459s006lbl.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib21","unstructured":"Food and Drug Administration, 2015. FDA News Release \u2013 FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose. \u3008https:\/\/wayback.archive-it.org\/7993\/20180125101447\/https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm473505.htm\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib22","unstructured":"Food and Drug Administration, 2016. FDA advisory committee on the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in the community settings. \u3008https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM522688.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1615145","article-title":"Addressing the fentanyl threat to public health","volume":"376","author":"Frank","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.ejphar.2018.08.004_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1213\/00000539-199403000-00021","article-title":"Comparison of potency and duration of action of nalmefene and naloxone","volume":"78","author":"Glass","year":"1994","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejphar.2018.08.004_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2013.06.010","article-title":"Respiratory stimulant drugs in the post-operative setting","volume":"189","author":"Golder","year":"2013","journal-title":"Resp. Physiol. Neurobiol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.resp.2009.02.011","article-title":"AMPAkine therapy to counter fentanyl-induced respiratory depression","volume":"168","author":"Greer","year":"2009","journal-title":"Resp. Physiol. Neurobiol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib28","unstructured":"Hedegaard, H., Warner, M., Mini\u00f1o, A.M., 2017. Drug overdose deaths in the United States, 1999\u20132016. NCHS Data Brief, no 294. Hyattsville, MD: National Center for Health Statistics. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at \u3008http:\/\/wonder.cdc.gov\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib29","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central \u03bc-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharm"},{"key":"10.1016\/j.ejphar.2018.08.004_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0196-0644(05)80200-8","article-title":"Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study","volume":"22","author":"Kaplan","year":"1993","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0196-0644(99)70270-2","article-title":"Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose","volume":"34","author":"Kaplan","year":"1999","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11419-016-0310-4","article-title":"Old opioids, new concerns: the case of acetylfentanyl","volume":"34","author":"Katselou","year":"2016","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib33","unstructured":"Katz, J., 2017. The first count of fentanyl deaths in 2016: up 540% in three years. \u3008https:\/\/www.nytimes.com\/interactive\/2017\/09\/02\/upshot\/fentanyl-drug-overdose-deaths.html\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/ALN.0000000000000634","article-title":"Opioid half-lives and hemlines: the long and short of fashion","volume":"122","author":"Kharasch","year":"2015","journal-title":"Anesthesiol"},{"key":"10.1016\/j.ejphar.2018.08.004_bib35","first-page":"1726","article-title":"Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system","volume":"38","author":"Kim","year":"1997","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jcph.759","article-title":"Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose","volume":"56","author":"Krieter","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Lynn","year":"2018","journal-title":"Ther. Adv. Drug. Saf."},{"key":"10.1016\/j.ejphar.2018.08.004_bib38","unstructured":"Mattingly, J., 2017. Synthetic heroin is too powerful for the overdose antidote. \u3008https:\/\/www.bloomberg.com\/news\/articles\/2017-08-16\/heroin-era-antidotes-can-t-handle-overdoses-in-age-of-synthetics\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib39","unstructured":"McCance-Katz, E., 2018. SAMSHA\/HHS: An update on the opioid crisis. \u3008https:\/\/www.samhsa.gov\/sites\/default\/files\/aatod_2018_final.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/add.14033","article-title":"Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study","volume":"113","author":"McDonald","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.ejphar.2018.08.004_bib41","first-page":"175","article-title":"Binding of a new opiate antagonist, nalmefene, to rat brain membranes","volume":"7","author":"Michel","year":"1985","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10550887.2016.1226582","article-title":"President's message: food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: what is a treatment advocate and educator to do?","volume":"35","author":"Morrone","year":"2016","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.ejphar.2018.08.004_bib43","unstructured":"Muhuri, P., Gfroerer, J., Davies, M., 2013. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. \u3008https:\/\/archive.samhsa.gov\/data\/2k13\/DataReview\/DR006\/nonmedical-pain-reliever-use-2013.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib44","unstructured":"National Institute on Drug Abuse, 2016. Fentanyl. \u3008https:\/\/www.drugabuse.gov\/publications\/drugfacts\/fentanyl\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/clpt.2009.194","article-title":"Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia","volume":"87","author":"Oertel","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2018.08.004_bib47","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/ALN.0b013e31819faa2a","article-title":"AMPAkine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats","volume":"110","author":"Ren","year":"2009","journal-title":"Anesthesiol"},{"key":"10.1016\/j.ejphar.2018.08.004_bib48","unstructured":"RespireRx Pharmaceuticals, 2016. Respiratory diseases product pipeline. \u3008http:\/\/respirerx.com\/product-pipeline\/\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib49","unstructured":"Rhyan, C., 2018. Economic Toll of Opioid Crisis in U.S. Exceeded $1 Trillion since 2001. \u3008https:\/\/altarum.org\/about\/news-and-events\/economic-toll-of-opioid-crisis-in-u-s-exceeded-1-trillion-since-2001\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib50","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in Drug and Opioid-Involved Overdose Deaths \u2014 United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ejphar.2018.08.004_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999\u20132015","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.ejphar.2018.08.004_bib52","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2018.08.004_bib53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib54","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the \u03bc-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.08.004_bib55","doi-asserted-by":"crossref","unstructured":"Solis, E., Cameron-Burr, K., Kiyatkin, E., 2017. Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia. eNeuro 23 October 2017, 4 (5) ENEURO.0323-17.2017; DOI: 10.1523\/ENEURO.0323-17.2017.","DOI":"10.1523\/ENEURO.0323-17.2017"},{"key":"10.1016\/j.ejphar.2018.08.004_bib56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/add.13209","article-title":"Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?","volume":"111","author":"Strang","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.ejphar.2018.08.004_bib57","unstructured":"Substance Abuse and Mental Health Services Administration, 2018. (SAMSHA). Preventing the consequences of opioid overdose: understanding naloxone access laws. \u3008https:\/\/www.samhsa.gov\/capt\/sites\/default\/files\/resources\/naloxone-access-laws-tool.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib58","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clinthera.2014.10.001","article-title":"Single and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers","volume":"37","author":"Turncliff","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2018.08.004_bib60","unstructured":"United States Drug Enforcement Administration, 2017. Fentanyl \u2013 a briefing guide for first responders.\u00a0\u3008https:\/\/www.dea.gov\/druginfo\/Fentanyl_BriefingGuideforFirstResponders_June2017.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ejphar.2018.08.004_bib62","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain- misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"NEJM"},{"key":"10.1016\/j.ejphar.2018.08.004_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.ejphar.2018.08.004_bib64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0736-4679(98)00019-5","article-title":"Nalmefene: a long-acting opioid antagonist. clinical application in emergency medicine","author":"Wang","year":"1998","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.ejphar.2018.08.004_bib65","unstructured":"Weiss, A., Bailey, M., O\u2019Malley, L., Barrett, M., Elixhauser, A., Steiner, C., 2017. Patient characteristics of opioid-related inpatient stays and emergency department visits nationally and by state, 2014. Statistical Brief #224, Agency for Healthcare Research and Quality (AHRQ). \u3008https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb224-Patient-Characteristics-Opioid-Hospital-Stays-ED-Visits-by-State.pdf\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bmcl.2008.10.134","article-title":"Syntheses and opioid receptor binding properties of carboxamido-substituted opioids","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.ejphar.2018.08.004_bib67","unstructured":"World Drug Report, 2016. \u3008https:\/\/www.unodc.org\/wdr2016\/\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib68","unstructured":"Yeginsu, C., 2018. Fentanyl adds deadly kick to opioid woes in Britain.\u00a0\u3008https:\/\/www.nytimes.com\/2018\/02\/04\/world\/europe\/uk-fentanyl-opioid-addiction.html?Hp&action=click&pgtype=Homepage&clickSource=story-heading&module=second-column-region&region=top-news&WT.nav=top-news\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2014.05.044","article-title":"Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats","volume":"738","author":"Yong","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.08.004_bib70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-100102181","article-title":"Comparative bioavailability study of a generic naltrexone tablet preparation","volume":"25","author":"Yuen","year":"1999","journal-title":"Drug Dev. Indust. Pharm."},{"key":"10.1016\/j.ejphar.2018.08.004_bib71","unstructured":"Zezima, K., 2018. Study: despite decline in prescriptions, opioid deaths skyrocketing due to heroin and synthetic drugs. \u3008https:\/\/www.washingtonpost.com\/amphtml\/news\/post-nation\/wp\/2018\/04\/10\/study-despite-decline-in-prescriptions-opioid-deaths-skyrocketing-due-to-heroin-and-synthetic-drugs\/\u3009. (Last Accessed May 2018)."},{"key":"10.1016\/j.ejphar.2018.08.004_bib72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3109\/10903127.2014.896961","article-title":"Pitfalls of intranasal naloxone","volume":"18","author":"Zuckerman","year":"2014","journal-title":"Prehosp. Emerg. Care"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:25:25Z","timestamp":1757975125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918304394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":72,"alternative-id":["S0014299918304394"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.004","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the front lines of the opioid epidemic: Rescue by naloxone","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}